Tenaya Therapeutics to Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Tenaya Therapeutics to Announce Initial Data From MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
An archived replay of the webcast will be available on Tenaya's website.Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET
公司定於12月17日星期二上午8:00（東部時間）召開電話會議
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17.
南舊金山，加利福尼亞州，2024年12月16日（全球新聞電訊）—— Tenaya Therapeutics，Inc.（納斯達克：TNYA），一家臨床階段的生物技術公司，致力於發現、開發和提供潛在治癒療法，以解決心臟病的根本原因，將於12月17日星期二宣佈TN-201基因治療在與MYBPC3相關的肥厚性心肌病（HCM）的MyPEAk-1階段1b/2臨床試驗中初步的第一組數據。
Conference Call and Webcast
Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register here. The live webcast will be available under the "Events" section of the Investor Relations page of the Tenaya website at investors.tenayatherapeutics.com.
電話會議和網絡直播
Tenaya管理團隊將於2024年12月17日星期二上午8:00（東部時間）舉行網絡直播和電話會議，以回顧MyPEAk-1的初步數據。要訪問直播，參與者可以在此註冊。網絡直播將在Tenaya網站的投資者關係頁面的「活動」部分提供，網址爲investors.tenayatherapeutics.com。
An archived replay of the webcast will be available on Tenaya's website.
網絡直播的存檔回放將在Tenaya的網站上提供。
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit .
關於Tenaya Therapeutics
Tenaya Therapeutics是一家臨床階段的生物技術公司，致力於一個大膽的使命：發現、開發和提供潛在的治癒療法，以應對心臟病的根本原因。Tenaya採用一系列整合的內部能力，包括與模式無關的靶標驗證、衣殼工程和製造，以生成一系列針對罕見遺傳疾病和更普遍的心臟病狀況的基因藥物。Tenaya的產品線包括TN-201，一種針對MYBPC3相關的肥厚型心肌病（HCM）的基因療法；TN-401，一種針對PKP2相關的心律失常右心室心肌病（ARVC）的基因療法；TN-301，一種用於保留射血分數的心力衰竭（HFpEF）的小分子HDAC6抑制劑；以及多個處於早期臨床前開發階段的項目。有關更多信息，請訪問。
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Tenaya 聯繫人
米歇爾·科拉爾
副總裁，企業傳播與投資者關係
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
投資者
安妮-瑪麗·菲爾茲
精準AQ
annemarie.fields@precisionaq.com
Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com
媒體
溫迪·賴安
Ten Bridge 通信董事
wendy@tenbridgecommunications.com
譯文內容由第三人軟體翻譯。